HOME >> BIOLOGY >> NEWS
REMICADE Phase 3 data show rapid, significant, long-term psoriasis improvement

, data was analyzed from the REMICADE 5 mg/kg every eight week maintenance arm of each trial, the only regimen common to both EXPRESS and EXPRESS II. At week 10, after infusions at weeks 0, 2, and 6, the proportions of patients achieving PASI 75 were 80 percent versus three percent of placebo patients for EXPRESS and 75 percent versus two percent of placebo patients for EXPRESS II, (both P < 0.001 versus placebo). At week 10, the proportions of patients achieving PASI 90, or nearly complete skin clearance, were 57 percent versus one percent of placebo patients for EXPRESS and 45 percent versus 0.5 percent of placebo patients for EXPRESS II, (both P < 0.001 versus placebo). PASI 75 responses achieved at week 10 were maintained through week 26 in both EXPRESS and EXPRESS II (81 percent and 78 percent of patients achieved at least PASI 75 improvement from baseline, respectively), and the majority of patients achieved PASI 75 at week 50 in the REMICADE 5 mg/kg every eight-week maintenance groups.

"These data show great potential for REMICADE in the treatment of a disease that often carries great physical and emotional challenges," said Robert Matheson, MD, Oregon Medical Research Center, and study investigator. "The potential of achieving nearly complete skin clearance is exciting and holds great promise for patients with this difficult to treat disease."

Investigators reported that at week 10 patients in both EXPRESS and EXPRESS II receiving REMICADE experienced improvements in the Dermatology Life Quality Index (DLQI) and Physician's Global Assessment (PGA), measures of quality of life and psoriasis severity, respectively. In both studies, following 5 mg/kg induction therapy, REMICADE-treated patients experienced a median improvement of nine points in DLQI, a change that is considered to be a clinically meaningful decrease in psoriasis-related burden for the patient, compared to no improvement for placebo patients (REMICADE vs. placebo, -9.0 ve
'"/>

Contact: Michael Parks
215-983-8000
Centocor, Inc.
3-Mar-2006


Page: 1 2 3

Related biology news :

1. Data in New England Journal of Medicine show benefits of REMICADE in ulcerative colitis patients
2. Active psoriatic arthritis patients on REMICADE achieve major clinical response in arthritis
3. Phase II study of therapeutic vaccine shows efficacy in patients with metastatic colorectal cancer
4. Biovest announces interim blinded data of fast-tracked pivotal Phase 3 clinical trial of BiovaxID
5. Oncolytics Biotech Inc. proceeds to initiate US Phase II sarcoma clinical trial
6. The Parkinsons Institute to conduct Phase III Clinical Trial of creatine for Parkinsons disease
7. Phase III trials of cellulose sulfate microbicide for HIV prevention closed
8. Phylonix awarded National Science Foundation Phase II SBIR for zebrafish screening
9. Kentucky first state to match federal SBIR-STTR Phase 1 and Phase 2 grants
10. Acorda announces positive Phase 3 Fampridine-SR study in people with multiple sclerosis
11. New Phase 3 data show potential benefits of Aranesp dosed every three weeks for CIA

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/6/2016)... 2016 Securus Technologies, a leading provider ... public safety, investigation, corrections and monitoring, and the ... five (5) year funding commitment by Securus to ... rehabilitation and reentry support to more inmates and ... 2004, the Prison Entrepreneurship Program (PEP) is an ...
(Date:12/2/2016)... , December 1, 2016 ... (Fingerprint, Voice), Future Technology (Iris Recognition System), Vehicle ... - Global Forecast to 2021", published by MarketsandMarkets, ... Million in 2016, and is projected to grow ... CAGR of 14.06%.      (Logo: http://photos.prnewswire.com/prnh/20160303/792302) ...
(Date:11/30/2016)... WARSAW, Poland , Nov. 30, 2016 Not many of us realize ... crucial aspects of recovery so we need to do it well. Inadequate sleep levels ... problems, high blood pressure, stroke, diabetes, and even cancer. Maybe now is ... Christmas present that could help them to manage their sleep quality? ... ...
Breaking Biology News(10 mins):
(Date:12/7/2016)... report "Acrylic Processing Aid Market by Polymer Type (PVC), Fabrication Process (Extrusion, Injection Molding), End-Use ... published by MarketsandMarkets, the global market size was USD 645.4 Million in 2016, ... CAGR of 6.2% between 2016 and 2026. Continue ... ... , , ...
(Date:12/7/2016)... 2016  Genprex, Inc. a biopharmaceutical company focused ... today announced that it has retained ICR Healthcare, ... communications and advisory firm, to develop and implement ... combine investor relations, public relations and digital communications ... of Genprex and its lead candidate Oncoprex, which ...
(Date:12/7/2016)... and ANN ARBOR, Mich. , ... biopharmaceutical company developing breakthrough immune modulatory medicines, announced today ... the Company,s lead therapeutic candidate, LYC-30937- E nteric ... a debilitating skin disease that is estimated to affect ... United States , with approximately 1.5 - 3 ...
(Date:12/7/2016)... CA (PRWEB) , ... December 07, 2016 , ... ... wastewater treatment and resource recovery solutions for industrial facilities, today announced that one ... be the first to use Cambrian’s novel water-energy purchase agreement (WEPA). Under the ...
Breaking Biology Technology:
Cached News: